eFFECTOR Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056859 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.38M
YoY Change 33.55%
Cash & Equivalents $15.51M
Short-Term Investments $9.875M
Other Short-Term Assets $867.0K
YoY Change -54.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.25M
YoY Change 25.63%
LONG-TERM ASSETS
Property, Plant & Equipment $190.0K
YoY Change -11.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $466.0K
YoY Change -35.55%
Total Long-Term Assets $881.0K
YoY Change -14.8%
TOTAL ASSETS
Total Short-Term Assets $26.25M
Total Long-Term Assets $881.0K
Total Assets $27.13M
YoY Change 23.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.713M
YoY Change -54.85%
Accrued Expenses $3.787M
YoY Change 48.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $18.92M
YoY Change -1.15%
Total Short-Term Liabilities $25.57M
YoY Change -4.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $735.0K
YoY Change 725.84%
Total Long-Term Liabilities $735.0K
YoY Change 725.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.57M
Total Long-Term Liabilities $735.0K
Total Liabilities $26.30M
YoY Change -1.63%
SHAREHOLDERS EQUITY
Retained Earnings -$188.2M
YoY Change 22.53%
Common Stock $0.00
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $827.0K
YoY Change
Total Liabilities & Shareholders Equity $27.13M
YoY Change 23.73%

Cashflow Statement

Concept 2024 Q2 2024 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001828522
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39866
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
eFFECTOR Therapeutics, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3306396
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
142 North Cedros Avenue
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
925-8215
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4704409
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15508000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14875000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
9875000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3495000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
867000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1468000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
26250000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19838000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
225000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53000
CY2024Q1 us-gaap Other Assets
OtherAssets
466000
CY2023Q4 us-gaap Other Assets
OtherAssets
513000
CY2024Q1 us-gaap Assets
Assets
27131000
CY2023Q4 us-gaap Assets
Assets
20544000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1713000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2330000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3787000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2921000
CY2024Q1 eftr Term Loans Net
TermLoansNet
18916000
CY2023Q4 eftr Term Loans Net
TermLoansNet
19385000
CY2024Q1 eftr Accrued Final Payment On Term Loans Current
AccruedFinalPaymentOnTermLoansCurrent
1100000
CY2023Q4 eftr Accrued Final Payment On Term Loans Current
AccruedFinalPaymentOnTermLoansCurrent
1100000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
53000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
25569000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25796000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
516000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
503000
CY2024Q1 eftr Non Current Warrant Liability
NonCurrentWarrantLiability
40000
CY2023Q4 eftr Non Current Warrant Liability
NonCurrentWarrantLiability
40000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
179000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q1 us-gaap Liabilities
Liabilities
26304000
CY2023Q4 us-gaap Liabilities
Liabilities
26339000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3914309
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3902309
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2994679
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2982679
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
189038000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173582000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188211000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179377000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
827000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5795000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27131000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20544000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5306000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6609000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3090000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2927000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
8396000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
9536000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8396000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9536000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
323000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
226000
CY2024Q1 us-gaap Interest Expense
InterestExpense
749000
CY2023Q1 us-gaap Interest Expense
InterestExpense
689000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-438000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-478000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8834000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10014000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8834000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10014000
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-19000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8834000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9995000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.96
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.96
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4081580
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4081580
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1680032
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1680032
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5795000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14446000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1010000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8834000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
827000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3896000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
119000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1167000
CY2023Q1 eftr Unrealized Loss On Short Term Investments
UnrealizedLossOnShortTermInvestments
19000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10014000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4813000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8834000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8834000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10014000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10014000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
CY2024Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
60000
CY2024Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
60000
CY2023Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
119000
CY2023Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
119000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1010000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1010000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1167000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1167000
CY2024Q1 eftr Other Expense Related To Equity Purchase Agreement
OtherExpenseRelatedToEquityPurchaseAgreement
12000
CY2024Q1 eftr Other Expense Related To Equity Purchase Agreement
OtherExpenseRelatedToEquityPurchaseAgreement
12000
CY2023Q1 eftr Other Expense Related To Equity Purchase Agreement
OtherExpenseRelatedToEquityPurchaseAgreement
15000
CY2023Q1 eftr Other Expense Related To Equity Purchase Agreement
OtherExpenseRelatedToEquityPurchaseAgreement
15000
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
87000
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
87000
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
76000
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
76000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-267000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-267000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
180000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
180000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-53000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-53000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-48000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-48000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-716000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-716000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2225000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2225000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7278000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7637000
CY2024Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
13000
CY2024Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
3500000
CY2023Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
12000000
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9821000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2960000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6321000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9027000
CY2024Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
556000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2024Q1 eftr Proceeds From Issuance Of Common Stock Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost
14787000
CY2023Q1 eftr Proceeds From Issuance Of Common Stock Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost
212000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14232000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
212000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
633000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1602000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14875000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8708000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15508000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10310000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
655000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
589000
CY2024Q1 eftr Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
186000
CY2023Q1 eftr Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
CY2024Q1 eftr Accrued Offering Costs
AccruedOfferingCosts
109000
CY2023Q1 eftr Accrued Offering Costs
AccruedOfferingCosts
170000
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-10-02
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188200000
CY2024Q1 eftr Cash From Operations
CashFromOperations
7300000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
25400000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
875000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-886000
CY2024Q1 eftr Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
0
CY2023Q1 eftr Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
3000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7278000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7637000
CY2024Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
13000
CY2024Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
3500000
CY2023Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
12000000
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9821000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2960000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6321000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9027000
CY2024Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
556000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2024Q1 eftr Proceeds From Issuance Of Common Stock Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost
14787000
CY2023Q1 eftr Proceeds From Issuance Of Common Stock Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost
212000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14232000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
212000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
633000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1602000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14875000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8708000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15508000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10310000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
655000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
589000
CY2024Q1 eftr Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
186000
CY2023Q1 eftr Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
CY2024Q1 eftr Accrued Offering Costs
AccruedOfferingCosts
109000
CY2023Q1 eftr Accrued Offering Costs
AccruedOfferingCosts
170000
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-10-02
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188200000
CY2024Q1 eftr Cash From Operations
CashFromOperations
7300000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
25400000
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28000
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3362805
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
926498
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9875000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2024Q1 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
9875000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
3495000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2023 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
3495000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
19444000
CY2024Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
528000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18916000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3362805
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
926498
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9875000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2024Q1 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
9875000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
3495000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2023 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
3495000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
542000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
464000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
352000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
324000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
542000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
464000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
352000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
324000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
190000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1587000
CY2024Q1 eftr Research And Development Current
ResearchAndDevelopmentCurrent
2461000
CY2023Q4 eftr Research And Development Current
ResearchAndDevelopmentCurrent
1036000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2024Q1 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
217000
CY2023Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
223000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3787000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2921000
CY2022Q1 eftr Extended Cut Off Date Before Which The Interest On Term Loan Paid
ExtendedCutOffDateBeforeWhichTheInterestOnTermLoanPaid
2024-03-01
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5000000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
1110000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1587000
CY2024Q1 eftr Research And Development Current
ResearchAndDevelopmentCurrent
2461000
CY2023Q4 eftr Research And Development Current
ResearchAndDevelopmentCurrent
1036000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2024Q1 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
217000
CY2023Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
223000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3787000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2921000
CY2022Q1 eftr Extended Cut Off Date Before Which The Interest On Term Loan Paid
ExtendedCutOffDateBeforeWhichTheInterestOnTermLoanPaid
2024-03-01
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5000000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6667000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6667000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
1110000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
19444000
CY2024Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
528000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18916000
CY2024Q1 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
5600000
CY2024Q1 eftr No Share Purchases Under The Purchase Agreement
NoSharePurchasesUnderThePurchaseAgreement
0
CY2023Q1 eftr No Share Purchases Under The Purchase Agreement
NoSharePurchasesUnderThePurchaseAgreement
0
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
100
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
110
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
19000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
14000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
225000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53000
CY2024Q1 eftr Right Of Use Assets Net
RightOfUseAssetsNet
225000
CY2023Q4 eftr Right Of Use Assets Net
RightOfUseAssetsNet
53000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
53000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
179000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
232000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
60000
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 eftr No Share Purchases Under The Purchase Agreement
NoSharePurchasesUnderThePurchaseAgreement
0
CY2023Q1 eftr No Share Purchases Under The Purchase Agreement
NoSharePurchasesUnderThePurchaseAgreement
0
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
110
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
480875
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.67
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
231800
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.32
CY2024Q1 eftr Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
P9Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
17911
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.53
CY2024Q1 eftr Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1
P3Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
694764
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.19
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1039000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
325122
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
56.29
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
151000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1000000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y9M18D
CY2024Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
2257426
CY2023 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
768592
CY2024Q1 eftr Placement Agent Warrants Issued And Outstanding
PlacementAgentWarrantsIssuedAndOutstanding
158017
CY2023Q4 eftr Placement Agent Warrants Issued And Outstanding
PlacementAgentWarrantsIssuedAndOutstanding
53799
CY2024Q1 eftr Pre Funded Warrants
PreFundedWarrants
653000
CY2023Q4 eftr Pre Funded Warrants
PreFundedWarrants
0
CY2024Q1 eftr Unvested Shares Held By Sponsors
UnvestedSharesHeldBySponsors
12000
CY2023Q4 eftr Unvested Shares Held By Sponsors
UnvestedSharesHeldBySponsors
12000
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
32293
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
96449
CY2024Q1 eftr Authorized For Future Issuances Under The Espp
AuthorizedForFutureIssuancesUnderTheEspp
89090
CY2023Q4 eftr Authorized For Future Issuances Under The Espp
AuthorizedForFutureIssuancesUnderTheEspp
59144
CY2024Q1 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
4137188
CY2023Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
1711457
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
27000000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
19000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
14000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
225000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53000
CY2024Q1 eftr Right Of Use Assets Net
RightOfUseAssetsNet
225000
CY2023Q4 eftr Right Of Use Assets Net
RightOfUseAssetsNet
53000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
56000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
77000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
79000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
68000
CY2024Q1 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
280000
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
48000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
232000
CY2024Q1 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
53000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
179000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.115
CY2024Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 eftr Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q1 eftr Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
56000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
77000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
79000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
68000
CY2024Q1 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
280000
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
48000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
232000
CY2024Q1 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
53000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
179000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.115
CY2024Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 eftr Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q1 eftr Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-056859-index-headers.html Edgar Link pending
0000950170-24-056859-index.html Edgar Link pending
0000950170-24-056859.txt Edgar Link pending
0000950170-24-056859-xbrl.zip Edgar Link pending
eftr-20240331.htm Edgar Link pending
eftr-20240331.xsd Edgar Link pending
eftr-ex31_1.htm Edgar Link pending
eftr-ex31_2.htm Edgar Link pending
eftr-ex32_1.htm Edgar Link pending
eftr-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eftr-20240331_htm.xml Edgar Link completed